This ‘self-regulating’ clearance mechanism means that pegfilgrastim is present throughout the neutrophil nadir and is eliminated from the circulation as neutrophil levels recover. This pharmacokinetic profile was seen in clinical trials across a wide range of tumour types and chemotherapy regimens.